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doi:10.1016/j.hkjn.2011.09.004Summary Background/Purpose: Early detection of chronic kidney disease (CKD) and its risk
factors such as hypertension (HT), diabetes (DM) and proteinuria will allow prompt medical
intervention, which may impact positively on kidney outcome. We took advantage of the World
Kidney Day, which is intended to raise awareness and increase the detection of CKD, to screen
participants for HT, DM and CKD using dipstick-positive proteinuria as a marker of CKD.
Methods: A total of 586 participants were screened for HT, DM and dipstick-positive protein-
uria during the 2009 World Kidney Day at Osogbo in southwest Nigeria.
Results: The overall prevalence of proteinuria, HT and DM in the unselected population was
2.5%, 25.9%, and 3.8%, respectively. Of participants with HT, there were more females (32.3%
vs. 21.9%, pZ 0.005), a higher prevalence of family history of HT (p < 0.001), older age
(p< 0.001), higher mean weight (p< 0.001), higher mean body mass index (p< 0.001) and high-
er mean random blood sugar (pZ 0.018) when compared to those without HT. However, among
the 461 apparently healthy participants (asymptomatic and without history of HT, DM or CKD),
the prevalence of significant dipstick-positive proteinuria, HT and DM was 2.8%, 11.1% and 2.0%,
respectively. In the asymptomatic cohort, age (odds ratio, 1.1; 95% confidence interval, 1.06e
1.14; p< 0.001) and sex (odds ratio, 2.68; 95% confidence interval, 1.2e5.95; pZ 0.016) were
significant risk factors associated with the presence of HT on multivariate analysis. Of partici-
pants with DM, there were more females (pZ 0.032), older age (pZ 0.019), higher mean body
mass index (pZ 0.008), higher mean systolic blood pressure (p< 0.001) and higher mean
diastolic blood pressure (pZ 0.011) when compared to those without DM.o.ca (O.E. Ayodele).
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56 O.E. Ayodele et al.Conclusion: Dipstick-positive proteinuria, HT and DM were common in our unselected and
asymptomatic population. Public education and opportunistic screening for these risk factors
of CKD will improve patient- and physician-level awareness, which in turn will ensure early
detection of kidney disease.
背景: 早期偵測慢性腎病 (CKD)及其危險因子如高血壓 (HT)、糖尿病 (DM)、及蛋白尿，有助於治
療的及早施行，可望對患者的預後產生正面的影響。我們為響應世界腎臟日對 CKD認知與偵測的
提倡，在相關活動當天對參加者進行了 HT、DM、及 CKD (蛋白尿試紙檢測)的篩檢行動。
方法: 該活動於尼日利亞奧索各博 (Oshogbo、Nigeria)的 2009年世界腎臟日進行，共有 586位參
加者接受了 HT、DM、及試紙蛋白尿的篩檢。
結果: 整體上，蛋白尿、HT、及 DM的盛行率分別為 2.5%、25.9%、及 3.8%。相比於非患者，HT
患者的特徵包括：女性比例較高 (32.3% vs. 21.9%、p Z 0.005)、HT 家族史比例較高
(p< 0.001)、較高齡 (p< 0.001)、體重較高 (p< 0.001)、身體質量指數較高 (p< 0.001)、及隨
機血糖較高 (pZ 0.018)。然而，在健康無異常 (無症狀、無 HT、DM、或 CKD 病史) 的參加者
(nZ 461) 間，試紙蛋白尿陽性、HT、及 DM 的盛行率分別為 2.8%、11.1%、及 2.0%。多變數分
析顯示，年齡 (OR、1.1；95% CI、1.06e1.14；p< 0.001) 及性別 (OR、2.68；95% CI、1.2
e5.95；pZ 0.016) 是 HT 的重大危險因子。相比於非患者，DM 患者的特徵則包括：女性比例較
高 (p Z 0.032)、較高齡 (p Z 0.019)、身體質量指數較高 (p Z 0.008)、收縮血壓較高
(p< 0.001)、及舒張血壓較高 (pZ 0.011)。
結論: 即使在未經挑選且無症狀的人群中，試紙蛋白尿陽性、HT、及 DM 仍然頗為盛行。透過有
效的衛生教育與篩檢措施，可望提升社會對 CKD的認知，並對患者作出及早的診治。7
Introduction
Chronic kidney failure (CKF), which represents the end of
the continuum of chronic kidney disease (CKD), is a devas-
tating medical illness with dire social and economic
consequences for the patients, their families and the
country.1,2 According to the World Health Organization,
genitourinary system disease was responsible for 1.6% of
total global deaths in 2004.3 The end-stage kidney disease
(ESKD) population and cost of treatment are projected to
exceed 3 million patients and US$1 trillion, respectively, by
the year 2010.4 Also, patients with CKD are 5e11 times
more likely to suffer premature death than to progress to
CKF.5
The prevalence of CKD in a population-based study6 in
the Democratic Republic of Congo (DRC) was 12.4%, which
is comparable to 11% in the US, 13% in Beijing and 14% in
Australia.7 The estimated incidence rate of CKF in Nigeria
is 400 per million population (pmp).8 However, the treat-
ment rate of ESKD in Africa varies from 670 pmp in Tunisia
to less than 20 pmp in most parts of Africa.7 The huge
disparity in the incidence and prevalence rates of ESKD
in most parts of Africa is due to excess mortality of these
patients consequent on limited availability of renal
replacement therapy as a result of absent or restricted
government funding or subsidy, high cost of renal
replacement therapy (estimated annual cost of dialysis in
Africa varies from US$8000 to US$12,000, which far exceeds
the gross domestic product per capita of most African
countries), paucity of dialysis units, restriction of these
units to urban areas and manpower shortages.7,9 However,
it is difficult to estimate the burden of CKF in most low-
and middle-income countries due to a lack of reliable
kidney registries.9
CKD is asymptomatic in the early stages, which often
results in delayed diagnosis and institution of appropriate
treatment.1,2 Various community surveys have also shown
that the knowledge and awareness of CKD are very lowin communities. Hypertension, glomerulonephritis and
diabetes, which are the leading causes of CKD in
Nigeria,10,11 can be detected early by the measurement of
blood pressure (BP), urine examination and estimation of
blood glucose, respectively. Early detection of these
diseases will allow prompt initiation of appropriate
educational and medical therapies, which may, in turn,
impact positively on kidney outcomes.
The magnitude of the existing burden of ESKD, the
projections for increasing incidence of CKD, the high cost
and lack of resources for renal replacement therapy in most
low- and middle-income countries with its attendant high
mortality, call for the prevention of CKD using an approach
based on awareness, early detection and effective treat-
ment.9 We took advantage of World Kidney Day, which is
intended to raise awareness and increase the detection of
CKD, to screen participants for hypertension, diabetes and
proteinuria.Methods
Three sites in Osogbo (a major trade center, the public
servant secretariat and the state broadcasting station)
were used for the screening exercise. The three sites were
chosen with the aim of reaching people in the formal and
informal work sectors and to ensure media coverage of the
screening exercise. We envisaged that the media coverage
would improve the awareness of the populace about the
need for routine screening for CKD due to the asymptom-
atic nature of early CKD. Osogbo is the capital of Osun State
in Southwest Nigeria (coordinates 746’N 434’E) and the
local government area has a population of 156,694 (2006
National Census figure). Consecutive participants who pre-
sented themselves for screening were enrolled in the
exercise. A structured questionnaire was used to obtain
information such as age, sex, marital status, personal and
family history of hypertension, diabetes and CKD. Each
Chronic kidney disease risk factors in Southwest Nigeria 57participant was asked whether their BP and blood sugar had
been checked in the 6 months prior to the screening
exercise.
The weight (in kilograms) of each participant, in light
clothing with the shoes off, was measured using bathroom
scales, and the height (in meters) was measured using
a stadiometer, so that body mass index (BMI) could be
calculated. Overweight and obesity were defined as BMI of
25e29.9 kg/m2 and 30 kg/m2, respectively.12
Each participant was allowed 5 minutes of rest before BP
measurement. Attempts were also made to ensure that
participants had not taken coffee or smoked a cigarette 30
minutes before their BP was taken.11 BP was measured with
each participant in a sitting position using the A&D UA-767
automated digital BP device (clinically validated by the
British Hypertension Society).13 Three BP readings were
taken for each participant and the average of the last two
readings was calculated and used for data analysis. BP
readings were classified according to the JNC 7 report.14
Normal BP was defined as systolic BP (SBP) <120 mmHg
and diastolic BP (DBP) < 80 mmHg. Prehypertension was
defined as SBP 120e139 mmHg and/or DBP 80e89 mmHg.11
Participants were classified as having hypertension if their
average SBP was 140 mmHg and/or average DBP was
90 mmHg, and/or they had a previous diagnosis of
hypertension by a health care worker and/or they were on
antihypertensive medication.14
Fingertip blood (OneTouch Ultra Easy Glucometer; Life-
Scan Inc., Milpitas, CA, USA) for fasting glucose or random
glucose was also performed. Diabetes mellitus was defined as
fasting blood sugar 7.0 mmol/L (126 mg/dL) or random
blood sugar (RBS)  11.1 mmol/L (200 mg/dL) and/or use of
glucose-lowering medication.15 Awareness of hypertension
and/or diabeteswas defined as self-reporting of any diagnosis
ofhypertensionand/ordiabetesbyahealthcareprofessional.
Each participant was instructed about urine sample
collection.16 A mid-stream urine specimen was collected
from each participant and urinalysis performed using Combi
9 Multistix (Bayer Diabetes Care, Basel, Switzerland)
immediately after voiding. Participants who were currently
menstruating or who had just completed menstruation
were excluded from urinalysis. Also, participants whose
urine sample was positive for nitrite and leukocytes, find-
ings which suggest urinary tract infection, were given forms
for urine microscopy, culture and sensitivity and subse-
quent treatment of urinary tract infection if confirmed. The
urine sample results from participants with likely urinary
tract infection were excluded from analysis. For the
purposes of this study, CKD was defined as dipstick-positive
proteinuria 1þ.17,18 Each participant gave informed oral
consent. Participants who were found to have elevated BP,
blood sugar and urinary abnormalities were referred to
a physician of their choice for further evaluation and
treatment. Ethics approval for the study was obtained from
the Research Ethics Committee of Ladoke Akintola Univer-
sity of Technology Teaching Hospital, Osun State, Nigeria.Statistical analyses
Continuous and categorical variables are displayed
as mean standard deviation (SD) and percentage,respectively. Student’s t test was used to assess differences
between means. Differences between categorical variables
were analyzed by the c2 test with Fisher’s exact correction
applied as appropriate. Differences between groups were
analyzed by analysis of variance. All p values were two-tailed
and values less than 0.05 were considered to be statistically
significant. To determine the contribution of various variables
associated with the presence of hypertension, diabetes and
CKD, only covariates with p values < 0.05 in the univariate
analysis were included in the logistic regression model.
Analyses were carried out using SPSS version 15 (SPSS Inc.,
Chicago, IL, USA).Results
A total of 586 participants [360 males (61.4%), 226 (38.6%)
females] took part in the screening exercise. Table 1 shows
the baseline demographic, personal and family histories,
and clinical characteristics of the study participants. Mean
age (SD) of the participants was 42.4 11.2 years. Female
participants were significantly older (43.8 10.3 years
vs. 41.5 11.7 years, pZ 0.014) and had higher BMI
(28.1 6.4 kg/m2 vs. 24.5 4.0 kg/m2, p< 0.001) than
males. However, the males were significantly taller than
the females (1.69 0.07 m vs. 1.59 0.06 m, p< 0.001).
The female participants had statistically significantly higher
DBP (74.5 13.7 mmHg vs. 72.0 12.2 mmHg, pZ 0.018)
and comparable SBP and RBS when compared to the males.
Ninety-six (16.4%) and 11 (1.9%) participants were
previously known to have hypertension and diabetes,
respectively, before the screening exercise. The preva-
lence of previously diagnosed diabetes before the screening
exercise was statistically significantly higher in the females
compared to the males (4.0% vs. 0.6%, pZ 0.003). There
was no statistically significant sex difference in the preva-
lence of previously diagnosed hypertension in the study
participants. More female participants had their BP
checked in the 6 months prior to the screening exercise
compared to males (49.1% vs. 40.3%, pZ 0.036). Overall,
less than half (43.7%) of the total participants had checked
their BP in the preceding 6 months. The number of partic-
ipants who had their blood sugar checked in the preceding 6
months was abysmally small (18.3%) and there was no
statistically significant sex difference. Family history of
hypertension and diabetes was significantly prevalent in the
female compared to the male participants (17.3% vs. 9.4%,
pZ 0.001 and 8.8% vs. 5.6%, pZ 0.025, respectively).
Seventy-two (13.3%) and 58 (10.7%) participants did not
know whether they had a family history of hypertension or
diabetes, respectively (data not shown).
Fourteen (2.5%) participants had visually positive dipstick
proteinuria 1þ. Although males with dipstick-positive
proteinuria outnumbered the females, the difference was
not statistically significant (2.9% vs. 1.9%, pZ 0.477). Partic-
ipants with dipstick-positive proteinuria had significantly
higher SBP (132.7 24.1 mmHg vs. 121.7 18.6 mmHg,
pZ 0.032)andDBP (80.1 15.9 mmHgvs.73.0 12.6 mmHg,
pZ 0.038) when compared to participants without protein-
uria (Table 2). However, there was no statistically significant
difference in the age, weight, height, BMI and RBS of partici-
pants with dipstick-positive proteinuria compared to those
Table 2 Characteristics associated with the presence of
proteinuria in the unselected study population.a
Dipstick positive
(nZ 14)
Dipstick negative
(nZ 541)
p
Sex
Male 10 (71.4) 336 (62.1) 0.477
Female 4 (28.6) 205 (37.9)
Age (y) 39.1 15.9 42.5 11.1 0.273
Educational status (nZ 553)
None 2 (14.2) 18 (3.3) 0.105
Primary 0 59 (10.9)
Secondary 6 (42.9) 211 (39.2)
Tertiary 6 (42.9) 251 (46.6)
Weight (kg) 67.6 19.8 70.7 14.3 0.440
Height (m) 1.66 0.08 1.66 0.07 0.910
BMI (kg/m2) 24.4 6.3 25.8 5.3 0.337
SBP (mmHg) 132.7 24.1 121.7 18.6 0.032
DBP (mmHg) 80.1 15.9 73.0 12.6 0.038
RBS (mmol/L) 6.6 2.3 6.6 2.3 0.948
BMIZ body mass index; DBPZ diastolic blood pressure;
RBSZ random blood sugar; SBPZ systolic blood pressure.
a Data are presented as n (%) or mean standard deviation.
Table 1 Baseline demographic and clinical characteristics, and personal and family histories of the study participants.a
Male
(nZ 360; 61.4%)
Female
(nZ 226; 38.6%)
Total (nZ 586) p
Age (y) 41.5 11.7 43.8 10.3 42.4 11.2 0.014
Educational status (nZ 584)
None 8 (2.2) 12 (5.4) 20 (3.4) 0.016
Primary 41 (11.4) 20 (8.9) 61 (10.4)
Secondary 155 (43.1) 75 (33.5) 230 (39.4)
Tertiary 156 (43.3) 117 (52.2) 273 (46.8)
Previously known to have HT 53 (14.7) 43 (19.0) 96 (16.4) 0.171
Previously known to have DM 2 (0.6) 9 (4.0) 11 (1.9) 0.003
Blood pressure checked in last 6 mo 145 (40.3) 111 (49.1) 256 (43.7) 0.036
Blood sugar checked in last 6 mo 61 (16.9) 46 (20.4) 107 (18.3) 0.298
Positive family history of HT 34 (9.4) 39 (17.3) 73 (12.5) 0.001
Positive family history of DM 20 (5.6) 20 (8.8) 40 (6.8) 0.025
Positive family history of kidney disease 2 (0.6) 1 (0.4) 3 (0.5) 0.228
Weight (kg) 70.4 13.0 71.3 16.7 70.7 14.5 0.459
Height (m) 1.69 0.07 1.59 0.06 1.65 0.08 < 0.001
BMI (kg/m2) 24.5 4.0 28.1 6.4 25.9 5.4 < 0.001
SBP (mmHg) 121.5 17.0 122.2 21.2 121.8 18.7 0.653
DBP (mmHg) 72.0 12.2 74.5 13.7 73.0 12.9 0.018
FBG (mmol/L) (nZ 43) 5.1 0.8 4.9 0.5 5.0 0.7 0.503
RBS (mmol/L) (nZ 497) 6.6 2.0 6.7 2.8 6.6 2.3 0.649
Newly diagnosed to have HT 26 (7.2) 30 (13.3) 56 (9.6) 0.015
Total no. of participants with HT 79 (21.9) 73 (32.3) 152 (26.0) 0.005
Newly diagnosed to have DM 7 (1.9) 4 (1.8) 11 (1.9) 0.88
Total no. of participants with DM 9 (2.5) 13 (5.8) 22 (3.8) 0.044
BMIZ body mass index; DBPZ diastolic blood pressure; DMZ diabetes mellitus; FBGZ fasting blood sugar; HTZ hypertension;
RBSZ random blood sugar; SBPZ systolic blood pressure.
a Data are presented as mean standard deviation or n (%).
58 O.E. Ayodele et al.withoutproteinuria.Three (0.5%)ofourparticipantshad trace
hematuria, while none had hematuria 1þ. Glycosuria was
present in 12 (2.2%) of the study cohort.
Fifty-six (9.6%) participants were newly diagnosed with
hypertension, while 96 (16.4%) were previously known to
have hypertension. Thus, the prevalence of hypertension in
the entire cohort was 26%. The prevalence of newly diag-
nosed hypertension was statistically significantly higher in
the females compared to the males (13.3% vs. 7.2%,
pZ 0.015). Also, the prevalence of hypertension in the
entire cohort was significantly higher in the female
participants (32.3% vs. 21.9%, pZ 0.005). Fifty-five (57.3%)
of the 96 participants with a previous diagnosis of hyper-
tension had BP < 140/90 mmHg.
Eleven (1.9%) participants were previously known to
have diabetes, while 11 (1.9%) were newly diagnosed with
diabetes. Thus, the prevalence of diabetes in the cohort
was 3.8%. There was no statistically significant sex differ-
ence in the prevalence of newly diagnosed diabetes.
However, the prevalence of diabetes in the entire cohort
was significantly higher in the females compared to the
males (5.8% vs. 2.5%, pZ 0.044). Only 5 of the 11 partici-
pants (i.e., 45.5%) with a previous diagnosis of diabetes had
RBS< 11.1 mmol/L (200 mg/dL).
The prevalence of overweight and obesity in the entire
study population was 28.8% and 19.6%, respectively. The
Chronic kidney disease risk factors in Southwest Nigeria 59respective prevalence of obesity and overweight was 30.0%
and 10.3% in the males and 27.0% and 34.5% in the females.
The prevalence of BMI 25 kg/m2 was statistically signifi-
cantly higher in the females compared to the males (61.5%
vs. 40.1%, p< 0.001).
On univariate analysis, participants with hypertension
had more females (32.3% vs. 21.9%, pZ 0.005), a higher
prevalence of family history of hypertension (23.7% vs.
8.5%, p< 0.001), were significantly older (50.0 9.6 years
vs. 39.7 10.5 years, p< 0.001), had higher mean weight
(75.1 16.1 kg vs. 69.2 13.6 kg, p< 0.001), higher mean
BMI (28.0 5.8 kg/m2 vs. 25.2 5.0 kg/m2, p< 0.001) and
higher mean RBS (7.1 3.2 mmol/L vs. 6.5 2.0 mmol/L,
pZ 0.018). However, participants without hypertension
were significantly taller than those with hypertension
(1.66 0.08 m vs. 1.64 0.08 m, pZ 0.011; Table 3). On
multivariate analysis, family history of hypertension [odds
ratio (OR), 9.2; 95% confidence interval (CI), 6.5e11.9;
p< 0.001] and age (OR, 1.5; 95% CI, 1.10e2.00; pZ
0.01) were only significantly associated with hypertension
(Table 3).
On univariate analysis, participants with diabetes had
more females (6.4% vs. 2.7%, pZ 0.032), were significantly
older (48.0 9.6 years vs. 42.2 11.4 years, pZ 0.019),
had higher mean BMI (28.7 4.6 kg/m2 vs. 25.7 5.4 kg/
m2, pZ 0.008), higher mean SBP (140.8 24.0 mmHg vs.
121.3 18.4 mmHg, p< 0.001) and higher mean DBP
(80.0 13.0 mmHg vs. 72.9 12.9 mmHg, pZ 0.011)
compared to those without diabetes (Table 4). However,
participants without diabetes were significantly taller than
those with diabetes (1.66 0.08 m vs. 1.61 0.10 m,
pZ 0.01). Only SBP was significantly associated with dia-
betes on multivariate analysis (Table 4).
In order to compare our findings with those of the
Screening for Hong Kong Asymptomatic Renal Population
(SHARE) program,17 we excluded participants with
a personal history of hypertension and/or diabetes and
those who did not have urinalysis done. Thus, 461 asymp-
tomatic participants were entered into the analysis
(Table 5). Our cohort was younger than the SHARE cohort
and almost half of our participants were < 40 years oldTable 3 Characteristics associated with the presence of hypert
Participants with
HT (nZ 152)
Par
HT
Sex
Male 73 (48.0) 153
Female 79 (52.0) 281
Age (y) 50.0 9.6 39.
Positive family history of HT 36 (23.7) 37 (
Weight (kg) 75.1 16.1 69.
Height (m) 1.64 0.08 1.6
BMI (kg/m2) 27.95 5.84 25.
SBP (mmHg) 142.2 20.4 114
DBP (mmHg) 85.6 12.7 68.
RBS (mmol/L) 7.1 3.2 6.5
BMIZ body mass index; DBPZ diastolic blood pressure; HTZ hyperte
a Data are presented as n (%) or mean standard deviation.compared with 18.8% of the SHARE cohort. The prevalence
rates of proteinuria and hematuria (1þ) were, respec-
tively, 2.8% and 0% in our cohort and 3.2% and 13.8% in the
SHARE participants. The prevalence of high normal BP was
higher in our participants compared to the SHARE cohort.
However, the prevalence rates of hypertension and isolated
systolic hypertension were higher in the SHARE participants
compared to ours (8.7% vs. 6.1% and 16.6% vs. 5.0%,
respectively). On univariate analysis, female sex, age,
weight and BMI were associated with hypertension
(Table 6). However, only sex (OR, 2.68; 95% CI, 1.20e5.95;
pZ 0.016) and age (OR, 1.10; 95% CI, 1.06e1.14; p< 0.001)
were significantly associated with hypertension on multi-
variate analysis of the asymptomatic cohort.Discussion
The prevalence of dipstick-positive proteinuria (1þ) and
hence CKD in our asymptomatic cohort was 2.8%. Although
our figure is comparable to the 3.2% obtained in the SHARE
program,17 it is much lower than the 17.1% reported by
Sumaili et al19 from the DRC in a similar World Kidney Day
screening exercise for proteinuria and CKD in 2007.
Participants with proteinuria had significantly higher SBP
and DBP when compared to those without proteinuria,
similar to findings from other studies. We did not find any
significant relationship between proteinuria and age,
weight, BMI, and the presence of diabetes, unlike the
report from the DRC. However, our finding may be due to
the small number of participants with proteinuria. None of
our participants had significant hematuria compared to
13.8% in the SHARE cohort. A likely explanation for this
marked disparity in the prevalence of hematuria is the
rarity of IgA nephropathy in the African population when
compared with the Asian population.20
The overall prevalence of hypertension in our study
cohort was 26%. This figure is higher than the 15.6% re-
ported from Nigeria in the International Collaborative Study
on Hypertension in Blacks (ICSHIB).21 The higher figure re-
ported in our study may not be unconnected with the factension in the unselected study population.a
ticipants without
(nZ 434)
p (univariate
analysis)
p (multivariate
analysis)
(35.3) 0.005 0.134
(64.7)
7 10.5 <0.001 <0.001
8.5) <0.001 0.10
2 13.6 <0.001 0.310
6 0.08 0.011 0.272
15 5.00 <0.001 0.912
.6 11.4 <0.001
6 9.6 <0.001
 2.0 0.018 0.097
nsion; RBSZ random blood sugar; SBPZ systolic blood pressure.
Table 4 Characteristics associated with the presence of diabetes in the unselected study population.a
Participants with
diabetes (nZ 22)
Participants without
diabetes (nZ 518)
p (univariate
analysis)
p (multivariate
analysis)
Sex
Male 13 (59.1) 189 (36.5) 0.032 0.654
Female 9 (40.9) 329 (63.5)
Age (y) 48.0 9.6 42.2 11.4 0.019 0.797
Positive family
history of HT
3 (13.6) 66 (12.7) 0.772 NE
Weight (kg) 74.9 14.3 70.5 14.5 0.165
Height (m) 1.61 0.10 1.66 0.08 0.01 0.310
BMI (kg/m2) 28.72 4.58 25.66 5.35 0.008 0.548
SBP (mmHg) 140.8 24.0 121.3 18.4 < 0.001 0.002
DBP (mmHg) 80.0 13.0 72.9 12.7 0.011 0.139
RBS (mmol/L) 14.2 6.3 6.3 1.2 < 0.001 NE
BMIZ body mass index; DBPZ diastolic blood pressure; HTZ hypertension; NEZ not entered into multivariate analysis; RBSZ random
blood sugar; SBPZ systolic blood pressure.
a Data are presented as n (%) or mean standard deviation.
Table 5 Results of the SHARE screening program and
those of the present study.
SHARE17
(nZ 1201)
Present study
(nZ 461)
Country of origin Hong Kong Nigeria
Year of screening 2003 2009
Race Chinese Nigerian
(Blacks)
Number (total) 1703 586
Number (asymptomatic) 1201 461
Age range (y) 20 18
Mean age (y)
Total 56.4 42.4
Asymptomatic 53.0 40.8
Age range (y)
40 226 (18.8) 230 (49.9)
41e60 641 (53.4) 218 (47.3)
61 334 (27.8) 13 (2.8)
Urinary abnormalities
Prevalence of
proteinuria (%)
39 (3.2) 13 (2.8)
Urine RBC (1þ) 166 (13.8) 0 (0)
Urine sugar 21 (1.7) 5 (1.1)
Blood pressure classification
Normal (129/84 mmHg) 869 (72.3) 352 (76.3)
High-normal (130e139/85
e89 mmHg)
29 (2.4) 58 (12.6)
Hypertension (140/
90 mmHg)
104 (8.7) 28 (6.1)
ISHT (140/<90 mmHg) 199 (16.6) 23 (5.0)
Newly diagnosed diabetes NA 9 (2.0)
ISHTZ isolated systolic hypertension; NAZ not available;
RBCZ red blood cells.
60 O.E. Ayodele et al.that our study was carried out in an urban setting, whereas
the ICSHIB was carried out in two low-income communities
in Nigeria with no substantial differences in lifestyle and
thus can be classified as rural. Various reports from Nigeria
and other African countries have consistently shown that
hypertension is more prevalent in urban than in rural
areas.21e23 Our figure is, however, comparable to the
prevalence of 27.6% in the DRC,6 24.6% in Cameroon,23
26.1% in China,24 but lower than the 29.4% reported from
Ghana25 and the 32.6% in Blacks in the US.26
Fifty-six (9.6%) study participants were newly diagnosed
with hypertension while 96 (16.4%) gave a self-reported
diagnosis of hypertension. The high level of awareness of
elevated BP or hypertension of 63.2% in our study cohort is
much higher than the 18e35% reported from various
community-based studies from Africa.25 This high level of
awareness in our cohort may be due to the fact that our
population is a biased one since participants who are more
concerned about their health, or those who had been
diagnosed to have hypertension, could have been over-
represented. The asymptomatic nature of hypertension
and the poor health-seeking habit of our cohort (< 50% had
had their BP checked in the 6 months prior to the screening
exercise) may be responsible for the prevalence of undi-
agnosed hypertension of about 10% in our study cohort. The
higher prevalence of hypertension in the female partici-
pants compared to the males can be explained by the
significantly more prevalent family history of hypertension
and higher mean age and BMI in the females compared to
the males.
The prevalence of overall hypertension (defined as BP
140/90 mmHg) in our asymptomatic population was
11.1% compared to 25.5% of the SHARE cohort.17 The SHARE
cohort was older than our participants and this may explain
the higher prevalence of hypertension in the SHARE study.
Determinants of hypertension on multivariate analysis in
the total population were family history of hypertension
and age. Our findings agree with other published studies
Table 6 Prevalence and risk factors for hypertension in the asymptomatic population.a
Normal BP Newly diagnosed HT Total Univariate
analysis
Multivariate analysis
p OR (95% CI) p
Total 410 (88.9) 51 (11.1) 416 (100)
Sex
Male 270 (91.5) 25 (8.5) 295 (64.0) 0.018 2.68 (1.20e5.95) 0.016
Female 140 (84.3) 26 (15.7) 166 (36.0)
Age (y) 39.8 10.6 49.3 10.8 40.8 11.0 <0.001 1.10 (1.06e1.14) <0.001
FHHT 37 (9.0) 5(9.8) 42 (9.1) 0.914 NE
FHDM 30 (7.3) 1 (2.0) 31 (6.7) 0.351 NE
FHCKD 3 (0.7) 0 (0) 3 (0.65) 0.338 NE
Weight (kg) 69.1 13.8 73.4 14.8 69.6 13.9 0.039 1.05 (0.99e1.10) 0.094
Height (m) 1.66 0.09 1.65 0.09 1.66 0.09 0.244 NE
BMI (kg/m2) 25.1 5.0 27.1 5.7 25.3 5.1 0.007 0.93 (0.81e1.07) 0.319
RBS (mmol/L) 6.5 1.8 6.8 1.8 6.5 1.8 0.284 NE
SBP (mmHg) 114.8 11.4 149.9 17.8 118.6 16.5 <0.001
DBP (mmHg) 68.8 9.5 89.6 11.6 71.1 11.7 <0.001
BMIZ body mass index; BPZ blood pressure; CIZ confidence interval; DBPZ diastolic blood pressure; FHCKDZ family history of
chronic kidney disease; FHDMZ family history of diabetes mellitus; FHHTZ family history of hypertension; HTZ hypertension;
NEZ not entered into multivariate analysis; ORZ odds ratio; RBSZ random blood sugar; SBPZ systolic blood pressure.
a Data are presented as n (%) or mean standard deviation.
Chronic kidney disease risk factors in Southwest Nigeria 61which have shown increasing prevalence of hypertension in
those with a family history of hypertension.27,28 Although
familial aggregation in hypertension is not sufficient to
infer genetic susceptibility because environmental and
cultural influences also aggregate in families, essential
hypertension is now thought to be a polygenic disease with
complexities such as geneegene and environmentegene
interactions.29 The finding of increasing prevalence of
hypertension with increasing age in our study participants is
similar to that in other published reports.25e27
Our findings of significant association between hyper-
tension, and family history of hypertension and increasing
age will argue for targeted screening in these particular
populations. However, to plan for screening and preventive
strategies in any community, the degree of health aware-
ness and the availability of human and material resources
must be taken into consideration.30 While targeted
screening has been advocated in high-income countries
because of its proven cost-effectiveness, whole population
screening may be more suitable for less sophisticated
health systems such as ours.31 This submission is based on
the fact that whole population screening will increase
awareness and detection rates of other non-communicable
diseases, which may in turn impact positively on treatment
and clinical outcome rates. The improved detection and
treatment rates and the cost-effectiveness of whole pop-
ulation screening have been proven in the Chennai project
in Southern India.32
Fifty-five (57.3%) participants with self-reported diag-
nosis of hypertension had BP< 140/90 mmHg. Suboptimal
BP control is associated with increased cardiovascular and
renal morbidity and mortality and substantial health care
expenditure. Lawes et al33 reported that a non-optimal
level of BP was responsible for 14% of global deaths and
6% of disability-adjusted life years lost in 2001. Similarly,Gaziano et al34 reported that suboptimal BP had a cost of
US$377 109 globally in 2001, which represented about 10%
of the world’s overall health care expenditure. In view of
the fact that we did not assess current intake of BP-
lowering medications (antihypertensives) and lifestyle
modifications in the participants with self-reported diag-
nosis of hypertension, it is difficult to assess the treatment
and control rates of hypertension in our participants.
The International Diabetes Federation estimated that
285 million adults aged 20e79 years currently have dia-
betes, and this global figure is expected to increase by 54%
to 439 million by 2030.35 Developing countries will account
for 69% of this increase while developed countries will
account for 20%.35 The increase in the prevalence of dia-
betes in developing countries is being driven by urbaniza-
tion, which is associated with more sedentary lifestyles,
physical inactivity, unhealthy diets and increasing preva-
lence of obesity and overweight.36 The prevalence of dia-
betes mellitus in our cohort was 3.8%, which is slightly
higher than the 2.0e2.8% from published studies from
Nigeria.36 The mean age of our participants with diabetes
was 49.0 9.6 years, which is in keeping with the report
from the International Diabetes Federation that diabetes
affects people aged between 40 and 60 years in developing
countries, in contrast to the developed world where the
majority of people with diabetes are over 60 years old.35
The major risk factors for diabetes from published studies
include urbanization, obesity, physical inactivity,
increasing age and ethnicity. It is therefore not surprising
that our participants with diabetes were significantly older
and had higher BMI than those without diabetes. The
significantly higher SBP and DBP in our participants with
diabetes lend credence to the hypothesis that insulin
resistance may be the common etiopathogenetic mecha-
nism in the development of diabetes and hypertension.37
62 O.E. Ayodele et al.Although diabetes is the leading cause of CKF globally, it is
the third most common cause of CKF in Nigeria. However,
a report from Nigeria indicated that diabetes is assuming an
increasing etiological role in CKF in Nigeria.7
The overall prevalence of obesity in our cohort was
19.6%, which is higher than the 8.8% (95% CI, 7.0e10.6%)
reported in a systematic review of obesity in Nigerians.38
However, recent publications from Nigeria have docu-
mented obesity rates varying from 17% to 22.3%.39,40 The
high prevalence of overweight and obesity in our partici-
pants may relate to their occupations and therefore their
levels of physical activity. Our participants were made up of
mainly public workers and market men and women whose
job descriptions involve sitting down for long periods of
time during the day. However, we did not estimate the
level of physical activity in our study participants. The
prevalence of obesity in our female participants was more
than thrice that of the males, which is consistent with
various reports from Nigeria and other sub-Saharan African
countries. Obesity in urban West Africa has more than
doubled (114%) over the last decade and this increase in
prevalence is largely being driven by the increasing preva-
lence of obesity in women.41
Our study has a few limitations. Firstly, this was an
opportunistic screening exercise and our study population
may be a biased one since participants who were more
concerned with their health or had been diagnosed to have
hypertension and/or diabetes could have been over-
represented. Thus, the prevalence of various diseases
obtained in this screening exercise may not be a true
reflection of these diseases in the community. Secondly,
most of the participants who were diagnosed to have
hypertension, diabetes and dipstick-positive proteinuria did
not come for follow-up in the Teaching Hospital for further
evaluation. Thus, the prevalence of these diseases by our
estimation could have been over-diagnosed since definitive
diagnosis of hypertension, diabetes and CKD requires that
BP, blood sugar and urinalysis be rechecked. Thirdly, in
view of cost and logistics, we were unable to screen for
microalbuminuria, which is an early marker of CKD.
However, dipstick-positive proteinuria has been used to
screen for CKD in many countries including Hong Kong and
Japan.17,42,43 In addition, observational studies have shown
that single-episode dipstick-positive proteinuria of 1þ
predicted ESKD and all-cause and cardiovascular mortality
in the general population.18 Fourthly, we were unable to
measure serum creatinine and subsequently estimate the
glomerular filtration rate. Lastly, although we did refer
participants with hypertension, diabetes and proteinuria to
health care facilities of their choice, we could not ascertain
definitively whether the participants eventually presented
at those facilities for further evaluation.
In conclusion, dipstick-positive proteinuria, hyperten-
sion and diabetes were common in our unselected and
asymptomatic population. In view of our findings, we
advocate that people should be encouraged to check their
urinalysis, BP, and blood sugar regularly. Also, the health-
seeking habit of our study participants was rather poor
going by the number of participants who had checked their
BP and blood sugar in the 6 months preceding the screening
exercise. Published studies on CKD awareness have shown
low patient- and provider-awareness. Screening for CKDwill increase patient-level awareness which may in turn
impact positively on provider-level awareness.44 Screening
also ensures early detection of CKD risk factors such as
hypertension and diabetes. Hypertension and proteinuria
are strong predictors of progressive kidney disease.45 BP
control and reduction of proteinuria have been shown to
not only reduce the number of people who need dialysis or
transplantation, and to reduce cardiovascular and ESKD
deaths, but also to be cost-effective.46,47 To optimize the
benefits derivable from such screening exercises, our
health sector must be re-organized in such a way that
opportunistic primary care-based screening are readily
available, accessible and affordable, and a feedback
system is entrenched in the health sector to ensure optimal
treatment and long-term follow-up to appraise the effec-
tiveness of such treatment. In addition, the populace
should be encouraged to engage in lifestyle modifications
such as frequent exercise, reduction and maintenance of
ideal body weight, low salt intake and adherence to the
DASH diet (from the Dietary Approaches to Stop Hyper-
tension study), which have been shown to reduce the
prevalence of hypertension, obesity and diabetes at
personal and community levels.48Acknowledgments
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